Skip to content

Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast Cancer

Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast Cancer

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07543107
Acronym
OFFLINE-PET-PR
Enrollment
30
Registered
2026-04-21
Start date
2026-04-16
Completion date
2028-08-31
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This is a single-arm, single-center, prospective observational study. It uses offline PET/CT to verify and quantify the range accuracy of hypofractionated proton radiotherapy for postoperative breast cancer. The correlation between range error and clinical toxicities (radiation pneumonitis, rib fracture) will be analyzed. A PET signal-proton range correlation model will be established using Monte Carlo simulation to provide evidence for optimizing proton therapy planning.

Interventions

OTHEROffline PET/CT scanning

Offline PET/CT scan performed after proton therapy to verify range accuracy; no therapeutic intervention

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Written informed consent obtained. 2. Female aged ≥18 years. 3. Pathologically confirmed breast cancer after curative surgery (breast-conserving or mastectomy) and indicated for postoperative adjuvant radiotherapy. 4. Scheduled to receive moderate or ultra-hypofractionated proton therapy. 5. KPS ≥80, expected survival \>5 years. 6. Well-healed surgical incision without infection. 7. Fertile females must use contraception for ≥1 month before screening and throughout the study.

Exclusion criteria

1. Pregnant or lactating female. 2. Severe non-neoplastic medical comorbidities precluding radiotherapy. 3. Inability to cooperate or comply with offline PET/CT examination.

Design outcomes

Primary

MeasureTime frameDescription
Proton beam range accuracy verified by offline PET/CTDuring proton radiotherapy (at the time of offline PET/CT scanning)Quantify the range accuracy of hypofractionated proton radiotherapy for breast cancer using offline PET/CT imaging
Correlation between range error and radiation pneumonitisUp to 24 months after completion of proton radiotherapyEvaluate the correlation between proton range error measured by offline PET/CT and the incidence of radiation pneumonitis
Correlation between range error and rib fractureUp to 24 months after completion of proton radiotherapyEvaluate the correlation between proton range error measured by offline PET/CT and the incidence of rib fracture

Secondary

MeasureTime frameDescription
Correlation between range error and lung dosimetric parametersDuring proton radiotherapyAnalyze the correlation between proton range error and lung V5, V10, V20
Correlation between range error and rib dosimetric parametersDuring proton radiotherapyAnalyze the correlation between proton range error and rib Dmax, V30
Performance of PET signal-proton range prediction modelDuring proton radiotherapyEstablish and evaluate the PET signal-proton range quantitative model using Monte Carlo simulation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026